Comparison of the effects of different potent adjuvants on enhancing the immunogenicity and cross-protection by influenza virus vaccination in young and aged mice.
Adjuvants, Immunologic
/ administration & dosage
Age Factors
Animals
Antibodies, Viral
/ blood
Cross Protection
/ immunology
Female
Humans
Immunity, Cellular
Immunogenicity, Vaccine
Influenza Vaccines
/ administration & dosage
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Orthomyxoviridae Infections
/ immunology
Th1 Cells
/ immunology
Th2 Cells
/ immunology
Vaccination
Adjuvant
Cross-protection
Influenza virus
Split vaccine
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
11
09
2021
revised:
03
12
2021
accepted:
16
12
2021
pubmed:
22
12
2021
medline:
25
2
2022
entrez:
21
12
2021
Statut:
ppublish
Résumé
Vaccination against influenza viruses suffers from low efficacy in conferring homologous and cross-protection, particularly in older adults. Here, we compared the effects of three different adjuvant types (QS-21+MPL, CpG+MPL and bacterial cell wall CWS) on enhancing the immunogenicity and homologous and heterosubtypic protection of influenza vaccination in young adult and aged mouse models. A combination of saponin QS-21 and monophosphoryl lipid A (QS-21+MPL) was most effective in inducing T helper type 1 (Th1) T cell and cross-reactive IgG as well as hemagglutination inhibiting antibody responses to influenza vaccination. Both combination adjuvants (QS-21+MPL and CpG+MPL) exhibited high potency by preventing weight loss and reducing viral loads and enhanced homologous and cross-protection by influenza vaccination in adult and aged mouse models. Bacillus Calmette-Guerin cell-wall skeleton (CWS) displayed substantial adjuvant effects on immune responses to influenza vaccination but lower adjuvant efficacy in inducing Th1 IgG responses, cross-protection in adult mice, and in conferring homologous protection in aged mice. This study has significance in comparing the effects of potent adjuvants on enhancing humoral and cellular immune responses to influenza virus vaccination, inducing homologous and cross-protection in adult and aged populations.
Identifiants
pubmed: 34933043
pii: S0166-3542(21)00219-9
doi: 10.1016/j.antiviral.2021.105229
pmc: PMC8801234
mid: NIHMS1767159
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
Influenza Vaccines
0
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
105229Subventions
Organisme : NIAID NIH HHS
ID : R01 AI093772
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI154656
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI147042
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
J Infect Dis. 1992 Jan;165(1):34-45
pubmed: 1727896
PLoS One. 2018 Jan 11;13(1):e0190868
pubmed: 29324805
NPJ Vaccines. 2017 Sep 8;2:25
pubmed: 29263880
J Gen Virol. 1999 Oct;80 ( Pt 10):2559-2564
pubmed: 10573147
Nature. 1988 Jul 21;334(6179):255-8
pubmed: 2456466
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726
pubmed: 32647056
Antiviral Res. 2018 Aug;156:107-115
pubmed: 29885376
PLoS Med. 2014 Jul 29;11(7):e1001685
pubmed: 25072396
Biomedicines. 2021 May 05;9(5):
pubmed: 34063125
N Engl J Med. 2018 Oct 25;379(17):1621-1634
pubmed: 30280651
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
Vaccine. 2010 Aug 16;28(36):5817-27
pubmed: 20600476
Vaccine. 2012 Apr 26;30(20):3126-35
pubmed: 22326899
J Exp Med. 1985 Jan 1;161(1):1-17
pubmed: 3918141
Infect Immun. 2000 Dec;68(12):6883-90
pubmed: 11083809
PLoS Curr. 2010 Mar 20;2:RRN1153
pubmed: 20352125
Expert Rev Vaccines. 2015;14(8):1125-34
pubmed: 26098721
Surg Today. 2009;39(3):194-200
pubmed: 19280277
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Virology. 2019 Sep;535:179-188
pubmed: 31310875
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
Semin Immunol. 2020 Aug;50:101426
pubmed: 33257234
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):757-61
pubmed: 21187388
Clin Vaccine Immunol. 2012 Dec;19(12):1943-8
pubmed: 23081815
Vaccine. 2019 Mar 7;37(11):1457-1466
pubmed: 30765169
Expert Rev Vaccines. 2013 Jan;12(1):13-30
pubmed: 23256736
Ann Pharmacother. 2018 Jul;52(7):673-680
pubmed: 29457489
Vaccine. 2020 Jul 31;38(35):5634-5646
pubmed: 32646816
J Immunol. 2017 Jan 1;198(1):279-291
pubmed: 27881702
Vaccine. 2020 Aug 10;38(36):5783-5792
pubmed: 32674907
Immun Ageing. 2020 Nov 19;17(1):37
pubmed: 33292323
Clin Infect Dis. 2020 Jan 2;70(2):181-190
pubmed: 30843046
Virology. 2019 Mar;529:111-121
pubmed: 30685658
Autophagy. 2010 Jan;6(1):46-60
pubmed: 19901560
JAMA. 2003 Jan 8;289(2):179-86
pubmed: 12517228
Infect Immun. 2003 Aug;71(8):4238-49
pubmed: 12874299
J Virol. 2016 Jul 11;90(15):6976-6988
pubmed: 27226368